| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 113.73 | 15.3% | 35.3% |
| Total Income | 113.73 | 15.3% | 35.3% |
| Expenditure | 91.54 | 6.2% | 25.6% |
| PBT | 22.85 | 75.6% | 100.1% |
| Net Profit | 16.75 | 74.1% | 106.8% |
| OPM | 19.51% | 6.97pp | 6.23pp |
| NPM | 14.73% | 4.97pp | 5.10pp |
| EPS | 0.11 | 57.1% | 120.0% |
MIMEDX Reports Q3 2025 Net Sales Up 35% YoY to $114MM
04 May 2026 · 4 May, 8:38 am
Summary
MIMEDX announced its Q3 2025 financial results, highlighting a 35% year-over-year increase in net sales to $114 million. The company reported a GAAP net income of $17 million and an adjusted EBITDA of $35 million, which is 31% of net sales. Free cash flow for the quarter was $29 million. The company is increasing its full year 2025 outlook, expecting revenue growth in the mid-to-high teens percentage basis and adjusted EBITDA margin in the mid-to-high 20s percentage basis.
Key Highlights
- 1
Net sales reached $114 million, reflecting a 35% increase year-over-year.
- 2
GAAP gross margin was 84%, while adjusted gross margin was 88%.
- 3
GAAP net income amounted to $17 million for the quarter.
- 4
Adjusted EBITDA was $35 million, representing 31% of net sales.
- 5
The company generated $29 million in free cash flow.
- 6
Surgical growth was strong at 26% year-over-year.
- 7
Net cash stood at $124 million at the end of Q3 2025.
Informational and educational content only. Not investment advice.